Biotech Values

[DewDiligence]

VRUS GILD BMY: I don't know much about the HBV space, but had just assumed that GILD was in total control at this point.

No—GILD does not dominate the HBV arena the way is does in HIV. To the contrary, BMY’s Baraclude is now the market leader in most countries.

Note that VRUS’ Clevudine is a pyrimidine analog, and hence it could sensibly be combined with either Baraclude or Viread, both of which are purine analogs.